RAHWAY, N.J.--(BUSINESS WIRE)--Feb 3, 2026-- Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2025. × Javascript is required …

Merck & Co., Inc. (NYSE:MRK) is among the most profitable healthcare stocks to buy. On January 21, TheFly reported that BofA analysts included Merck & Co., Inc. (NYSE:MRK) in its “US 1 List,” which includes the firm’s top investment ideas. A day …

At the close, the Dow Jones Industrial Average was down 0.34% at 49.240.99, while the S&P 500 shed 0.84% to 6,917.81 and the Nasdaq Composite saw out the session 1.43% weaker at 23,255.19. The Dow closed 166.67 points lower on Tuesday, taking a bite …

A recent development in the treatment of recurrent advanced clear cell renal cell carcinoma (ccRCC) is the approval of the HIF2α inhibitor belzutifan (Welireg). Sumanta K. Pal, MD, FASCO, professor, Department of Medical Oncology & Therapeutics …

Tuesday, February 3rd, 2026 Kicking off another day of trading, the Dow is flat but other indexes are up: the S&P 500 +0.23%, the Nasdaq +0.51% and the small-cap Russell 2000 +0.32%. The rebound off Friday’s near-term lows continues at a somewhat …

Merck (MRK) reported $16.4 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 5%. EPS of $2.04 for the same period compares to $1.72 a year ago. The reported revenue represents a surprise of +1.33% over the …

The S&P 500 Index ($SPX) (SPY) today is down -0.58%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.07%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.24%.   Stock indexes are mixed today, with the Nasdaq down significantly despite robust …

The animal parasiticides market is led by key companies such as Zoetis Services LLC, Merck & Co., Inc., Elanco, and Boehringer Ingelheim, Vetoquinol and more. PUNE, MAHARASHTRA, INDIA, February 3, 2026 /⁨EINPresswire.com⁩/ -- Animal …

Roughly a quarter of the S&P 500 reports earnings this week, and investors are no longer satisfied with glossy talk about "innovation". They want proof. Analysts now expect nearly 11% earnings growth for S&P 500 companies in the December …

Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts had expected as the drugmaker prepares for the loss of exclusivity of several of its medicines. MSD reported Q4 global sales of $ …